These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

292 related articles for article (PubMed ID: 36335234)

  • 1. The estimation of health state utility values in rare diseases: do the approaches in submissions for NICE technology appraisals reflect the existing literature? A scoping review.
    Meregaglia M; Nicod E; Drummond M
    Eur J Health Econ; 2023 Sep; 24(7):1151-1216. PubMed ID: 36335234
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Utility values in National Institute for Health and Clinical Excellence (NICE) Technology Appraisals.
    Tosh JC; Longworth LJ; George E
    Value Health; 2011 Jan; 14(1):102-9. PubMed ID: 21211492
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Consideration of quality of life in the health technology assessments of rare disease treatments.
    Nicod E; Meregaglia M; Whittal A; Upadhyaya S; Facey K; Drummond M
    Eur J Health Econ; 2022 Jun; 23(4):645-669. PubMed ID: 34714428
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A Review of the Methods Used to Generate Utility Values in NICE Technology Assessments for Children and Adolescents.
    Hill H; Rowen D; Pennington B; Wong R; Wailoo A
    Value Health; 2020 Jul; 23(7):907-917. PubMed ID: 32762993
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A systematic literature review of health state utility values in head and neck cancer.
    Meregaglia M; Cairns J
    Health Qual Life Outcomes; 2017 Sep; 15(1):174. PubMed ID: 28865475
    [TBL] [Abstract][Full Text] [Related]  

  • 6. 'Mapping' Health State Utility Values from Non-preference-Based Measures: A Systematic Literature Review in Rare Diseases.
    Meregaglia M; Whittal A; Nicod E; Drummond M
    Pharmacoeconomics; 2020 Jun; 38(6):557-574. PubMed ID: 32152892
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Evidence Review Group approaches to the critical appraisal of manufacturer submissions for the NICE STA process: a mapping study and thematic analysis.
    Kaltenthaler E; Boland A; Carroll C; Dickson R; Fitzgerald P; Papaioannou D
    Health Technol Assess; 2011 May; 15(22):1-82, iii-iv. PubMed ID: 21561569
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Health-state utility estimates for health technology assessment: a review of the manufacturers' submissions to the French National Authority for Health.
    Hamers FF; Ghabri S; Le Gales C
    Expert Rev Pharmacoecon Outcomes Res; 2017 Oct; 17(5):489-494. PubMed ID: 28133977
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Acceptability of Manufacturer-Proposed Utility Values for NICE Cancer Medicine Appraisals: Analysis of Manufacturers' Information Sources.
    Takada S; Narukawa M
    Int J Technol Assess Health Care; 2022 Mar; 38(1):e25. PubMed ID: 35297362
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Health state utility values in major depressive disorder treated with pharmacological interventions: a systematic literature review.
    Brockbank J; Krause T; Moss E; Pedersen AM; Mørup MF; Ahdesmäki O; Vaughan J; Brodtkorb TH
    Health Qual Life Outcomes; 2021 Mar; 19(1):94. PubMed ID: 33736649
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Health Technology Assessment Reports for Non-Oncology Medications in Canada from 2018 to 2022: Methodological Critiques on Manufacturers' Submissions and a Comparison between Manufacturer and Canadian Agency for Drugs and Technologies in Health (CADTH) Analyses.
    Mirzayeh Fashami F; Tarride JE; Sadeghirad B; Hariri K; Peyrovinasab A; Levine M
    Pharmacoecon Open; 2024 Nov; 8(6):823-836. PubMed ID: 39103675
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The impact of rarity in NICE's health technology appraisals.
    Clarke S; Ellis M; Brownrigg J
    Orphanet J Rare Dis; 2021 May; 16(1):218. PubMed ID: 33985575
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Inclusion of Carer Health-Related Quality of Life in National Institute for Health and Care Excellence Appraisals.
    Pennington BM
    Value Health; 2020 Oct; 23(10):1349-1357. PubMed ID: 33032779
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Economic Modeling Considerations for Rare Diseases.
    Pearson I; Rothwell B; Olaye A; Knight C
    Value Health; 2018 May; 21(5):515-524. PubMed ID: 29753347
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Does Methodological Guidance Produce Consistency? A Review of Methodological Consistency in Breast Cancer Utility Value Measurement in NICE Single Technology Appraisals.
    Rose M; Rice S; Craig D
    Pharmacoecon Open; 2018 Jun; 2(2):97-107. PubMed ID: 29623616
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Modelling approaches for histology-independent cancer drugs to inform NICE appraisals: a systematic review and decision-framework.
    Murphy P; Glynn D; Dias S; Hodgson R; Claxton L; Beresford L; Cooper K; Tappenden P; Ennis K; Grosso A; Wright K; Cantrell A; Stevenson M; Palmer S
    Health Technol Assess; 2021 Dec; 25(76):1-228. PubMed ID: 34990339
    [TBL] [Abstract][Full Text] [Related]  

  • 17. How Do Pharmaceutical Companies Model Survival of Cancer Patients? A Review of NICE Single Technology Appraisals in 2017.
    Gallacher D; Auguste P; Connock M
    Int J Technol Assess Health Care; 2019 Jan; 35(2):160-167. PubMed ID: 31017564
    [TBL] [Abstract][Full Text] [Related]  

  • 18.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 19.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 15.